Drug Trial Radar · NCT06858319
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Jun 25, 2031
Study completion Jun 25, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
Conditions
- Kidney Diseases
- Kidney Diseases, Chronic
- Urological Diseases
- Glomerulonephritis
- Glomerular Disease
- Glomerulonephritis, IGA
- Glomerulopathy
- Immunoglobulin Disease
Interventions
zigakibartDrug
solution for subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events.Time frame: Date of first administration of study treatment to 24 weeks after the date of the last actual administration of study treatment
- Number of participants with serious adverse events.Time frame: Date of first administration of study treatment to 24 weeks after the date of the last actual administration of study treatment
- Number of participants with adverse events of special interest.Time frame: Date of first administration of study treatment to 24 weeks after the date of the last actual administration of study treatment
Locations
26 sites in 9 countries. Site status is shown where the registry gives one.
Colorado Kidney Care Nephrology
Denver, Colorado · Recruiting
Nephrology Associates Of Central FL
Orlando, Florida · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
NY Nephrology
Clifton Park, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Knoxville Kidney Center Pllc
Brentwood, Tennessee · Recruiting
Dallas Renal Group
Dallas, Texas · Recruiting
Dallas Renal Group
Dallas, Texas · Recruiting
Nephro Asso North Illinois Indiana
Houston, Texas · Recruiting
Novartis Investigative Site
Santa Fe, Argentina · Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
La Plata, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Novartis Investigative Site
Catamarca, Catamarca Province, Argentina · Recruiting
Novartis Investigative Site
Gosford, New South Wales, Australia · Recruiting
Novartis Investigative Site
Kogarah, New South Wales, Australia · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Kuala Lumpur, Malaysia · Recruiting
Novartis Investigative Site
Kuantan, Pahang, Malaysia · Recruiting
Novartis Investigative Site
Monterrey, Nuevo León, Mexico · Recruiting
Novartis Investigative Site
Cheonan, Chungcheongnam-do, South Korea · Recruiting
Novartis Investigative Site
Guri-si, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Novartis Investigative Site
Girona, Catalonia, Spain · Recruiting
Novartis Investigative Site
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.